| ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------|-------------------------------------------------------------------------------------------|
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------|------------------------------------------------------------------------------------------|
|                    |   |                                   |
|-------------------------|--------|----------------------------------------|
| Delaware                |   | 06-1591613                             |
| (State of organization) |   | (I.R.S. EmployerIdentification Number) |
|                                    |   |                                                  |
|-----------------------------------------|--------|-------------------------------------------------------|
|  Title of Each Class          |   |  Name of Each Exchange on Which Registered  |
| Common stock, par value $0.01 per share |   | The NASDAQ Stock Market LLC                           |
|                              |   |    |         |                                |   |    |
|-----------------------------------|--------|---------|--------------|-------------------------------------|--------|---------|
| Large accelerated filer |   | ☐ |    | Accelerated filer              |   | ☒ |
|                              |   |    |         |
| Non-accelerated filer             |   | ☐ |    | Smaller reporting company |   | ☐ |

----

----

|                | MACROGENICS, INC. |
|---------------------|-------------------|
|                |              |   |
|                | BY:               | /s/ Scott Koenig |
|                |              | Scott Koenig, M.D., Ph.D. |
|                |              | President and Chief Executive Officer |
|                |              | (Principal Executive Officer) |
|                |              |   |
|                | BY:               | /s/ James Karrels |
|                |              | James Karrels |
|                |              | Senior Vice President and Chief Financial Officer |
|                |              | (Principal Financial Officer) |
|                |              |   |
| Dated: June 5, 2015 |              |   |

----

|                       |         |                                                                                                                                                           |         |                      |         |           |         |             |         |   |         |   |
|----------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------------|--------------|----------------|--------------|------------------|--------------|--------|--------------|--------|
|  Exhibit Number  |    | Exhibit Description                                                                                                                                            |    | Incorporated by Reference |    | Filed Herewith |
|                  |    | Form                                                                                                                                                           |    | File No.             |    | Exhibit        |    | Filing Date |    |
|                       |         |                                                                                                                                                           |         |                      |         |           |
| 4.3*                       |         | Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014                                           |    |                      |    |           |    |             |    |   |    | X      |
|                       |         |                                                                                                                                                           |         |                      |         |           |
| 10.25*                     |    | Collaboration and License Agreement by and between Janssen Biotech, Inc. and the Company, dated December 19, 2014.                                             |    |                      |    |           |    |             |    |   |    | X      |
|                       |         |                                                                                                                                                           |         |                      |         |           |
| 31.1                       |    | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |    |                      |    |           |    |             |    |   |    | X      |
|                       |         |                                                                                                                                                           |         |                      |         |           |
| 31.2                       |    | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |    |                      |    |           |    |             |    |   |    | X      |
| * | Confidential treatment has been requested with respect to certain portions of this exhibit. |
|---|---------------------------------------------------------------------------------------------|